Senti Biosciences公司近期公布了其或有价值权（CVR）相关的财务里程碑细节。根据协议条款，该公司在达成特定研发与商业目标时，将获得相应的里程碑付款。
具体而言，当公司成功提交生物制品许可申请（BLA）时，可获得1000万美元的付款。若该申请随后获得美国食品药品监督管理局（FDA）的批准，将再获得2000万美元。此外，当相关产品的年度净销售额达到2亿美元时，公司还将有资格获得一笔3000万美元的付款。
这些财务激励措施与公司核心管线的关键进展直接挂钩，旨在推动其疗法从研发阶段向商业化成功迈进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.